MedTrace Logo

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

NCT01716533 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2019-06-07

Study results available
· View outcomes & findings →

Summary

This study aims to 1) evaluate the C. difficile-specific immune response in CDI patients and 2) explore the difference in immune response between the patients with CDI recurrence and those with a sustained clinical response.

Conditions

  • Infections, Clostridium Difficile

Interventions

PROCEDURE

Blood sampling

Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.

OTHER

Stool sample collection

Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-02
Primary Completion
2015-06-01
Completion
2015-06-01

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716533 on ClinicalTrials.gov